A Prospective Study on the Detection of Gastric Neoplasms Using Pepsinogen and Gastrin-17 Levels.

ABSTRACT:

Background/aims

GastroPanel tests include gastrin-17 (G-17) levels in addition to pepsinogen (PG) and Helicobacter pylori serology tests. The aim of this study was to identify significant test findings in patients with gastric neoplasms by comparing the findings of GastroPanel tests and conventional serum PG assays.

Methods

Consecutive individuals who underwent serological testing were included from May 2023 to August 2024. Foreigners and those with gastrectomy, renal insufficiency, previous H. pylori eradication, and recent acid suppressant use were excluded.

Results

Among the 1,101 participants, 122 were diagnosed with gastric neoplasms. High G-17 levels (odds ratio [OR], 1.030; 95% confidence interval [CI], 1.008 to 1.052), low I/II ratios determined

SUBMITTER: Lee SY 

PROVIDER: S-EPMC12261124 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature